Background-Humans with an R302Q mutation in AMPK␥ 2 (the PRKAG2 gene) develop a glycogen storage cardiomyopathy characterized by a familial form of Wolff-Parkinson-White syndrome and cardiac hypertrophy. This phenotype is recapitulated in transgenic mice with cardiomyocyte-restricted expression of AMPK␥ 2 R302Q. Although considerable information is known regarding the consequences of harboring the ␥ 2 R302Q mutation, little is known about the early signaling events that contribute to the development of this cardiomyopathy. Methods and Results-To distinguish the direct effects of ␥ 2 R302Q expression from later compensatory alterations in signaling, we used transgenic mice expressing either the wild-type AMPK␥ 2 subunit (TG␥ 2 WT) or the mutated form (TG␥ 2 R302Q), in combination with acute expression of these proteins in neonatal rat cardiomyocytes. Although acute expression of ␥ 2 R302Q induces AMPK activation and upregulation of glycogen synthase and AS160, with an associated increase in glycogen content, AMPK activity, glycogen synthase activity, and AS160 expression are reduced in hearts from TG␥ 2 R302Q mice, likely in response to the existing 37-fold increase in glycogen. Interestingly, ␥ 2 WT expression has similar, yet less marked effects than ␥ 2 R302Q expression in both cardiomyocytes and hearts. Conclusions-Using acute and chronic models of ␥ 2 R302Q expression, we have differentiated the direct effects of the ␥ 2 R302Q mutation from eventual compensatory modifications. Our data suggest that expression of ␥ 2 R302Q induces AMPK activation and the eventual increase in glycogen content, a finding that is masked in hearts from transgenic adult mice. These findings are the first to highlight temporal differences in the effects of the PRKAG2 R302Q mutation on cardiac metabolic signaling events. (Circ Cardiovasc Genet. 2009;2:457-466.)
A MP-activated protein kinase (AMPK) is a highly conserved kinase that is responsible for controlling cellular energy homeostasis (for review, see reference 1). In the cardiomyocyte, AMPK has been implicated in stimulating myocardial fatty acid uptake 2 and oxidation 3 as well as glucose uptake, 4 glycolysis, 5, 6 and possibly glycogen storage or mobilization 6 -8 ; all of which likely contribute to maintaining adequate ATP supply that is necessary for normal cardiac function. In noncardiac cells, AMPK plays important roles in the regulation of many pathways including gluconeogenesis, fatty acid synthesis, lipolysis, whole-body metabolism (reviewed in reference 9), and appetite. 10 As a result of these studies, and given the fact that the antidiabetic drug metformin has been shown to increase AMPK activity, 12 there has been considerable interest in developing therapies that modulate AMPK activity for the treatment of obesity and diabetes. 11 Moreover,
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pharmacological activation of AMPK has also been proposed as a treatment for limiting myocardial ischemia and reperfusion injury. 13, 14 However, given the existence of naturally occurring gain-and loss-of-function mutations in AMPK and their association with certain cardiac abnormalities, [15] [16] [17] it is imperative that we first gain fundamental insight into the roles that AMPK plays in the heart before pursuing these therapeutic strategies. Studying and understanding these naturally occurring mutations will greatly assist in this endeavor.
AMPK consists of a catalytic subunit (␣) and 2 regulatory subunits (␤, ␥). 18, 19 The ␥ subunit of AMPK has been shown to bind AMP, 20 which ultimately enhances phosphorylation and activation of the ␣ subunit to increase AMPK activity. A number of mutations within the AMPK␥ 2 gene (PRKAG2) have been shown to produce a glycogen storage cardiomyopathy distinguished by ventricular preexcitation, progressive conduction system disease and in certain cases, cardiac hypertrophy. [15] [16] [17] It is believed that conduction system abnormalities present in these patients are a result of glycogenfilled myocytes causing bypass tracts and/or disruption of the annulus fibrosis between the atria and ventricle, 16, 17 faster depolarization of the ventricular myocardium and resulting tachycardia. 21 This cardiac phenotype in humans can be caused by a missense mutation in the human PRKAG2 gene that results in an arginine substitution with a glutamine at amino acid 302 (R302Q) in the ␥ 2 subunit. 15 In transgenic mice overexpressing the ␥ 2 R302Q mutation, the ␥ 2 N488I mutation, or the ␥ 2 R531G mutation, the resulting phenotypes include significant glycogen accumulation within the cardiomyocyte and marked cardiac hypertrophy. [22] [23] [24] This phenotype has been attributed to alterations in AMPK activity resulting from the mutations. However, the ␥ 2 R302Q and ␥ 2 R531G mutations have been reported to inhibit AMPK activity, whereas the ␥ 2 N448I mutation results in AMPK activation. 17, 23, 24 To date, it is not known how mutations causing either a decrease or an increase in AMPK activity might result in the same phenotype. Interestingly, evidence demonstrating changes in AMPK activity resulting from the mutations largely come from transgenic mice. 17, 23, 24 However, when studying adult mice from these transgenic lines, it is difficult to separate direct effects of the mutation alone from compensatory changes induced as a result of altered metabolism and glycogen accumulation. In fact, it has been shown that AMPK activity in hearts of transgenic mice expressing the ␥ 2 N488I mutation fluctuates in response to the levels of glycogen accumulation. 25 Therefore, based on these complex interactions between AMPK and glycogen accumulation in the young and the adult heart, the objective of this investigation was to distinguish the acute, direct effects of the ␥ 2 R302Q mutation from the chronic, potentially compensatory effects on AMPK activity and on pathways involved in glycogen accumulation and hypertrophic growth. Ultimately, the information gained from this study may provide clues as to the importance of AMPK activity, glycogen deposition, and cardiac hypertrophy in the development of the PRKAG2 syndrome. In addition, this mutation may also provide further information about the fundamental roles of AMPK in the heart and the effects of direct alteration of AMPK activity. This information is especially relevant given the interest in AMPK as a drug target for the treatment of obesity and/or diabetes and ischemia and reperfusion injury.
Methods

Animal Care
The University of Alberta adheres to the principles for biomedical research involving animals developed by the Council for International Organizations of Medical Sciences and complies with National Institutes of Health animal care guidelines.
Materials
Primary antibodies against phospho-Akt (Ser 473), Akt, phospho-AMPK␣ (Thr 172), AMPK␣, AMPK␥ 2 , AMPK␤ 2 , phospho-acetyl CoA carboxylase (Ser 79), phospho-Ser/Thr Akt substrate, AS160, glycogen synthase (GS), and phospho-p70S6K (Thr 389) were purchased from Cell Signaling Technology (Danvers, Mass). The primary antibody against phospho-GS (Ser641/5) was purchased from Novus Biologicals (Littleton, Colo). The primary antibodies against actin-and peroxidase-labeled streptavidin as well as secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, Calif). Radiolabeled substrates were purchased from Perkin-Elmer Life Sciences, Inc (Waltham, Mass).
Transgenic Mice
Transgenic mice with cardiomyocyte-restricted expression of the wild-type (TG␥ 2 WT) and the mutant human PRKAG2 gene (TG␥ 2 R302Q; substitution of glutamine for arginine at residue 302) were generated with the cardiac specific promoter ␣-myosin heavy chain as we have previously described. 24 Male and female mice were weighed before euthanasia (whole body weight). Hearts were extracted from 2-to 5-month-old mice, rinsed in ice-cold PBS, and total heart weight (HW) was determined. Hearts from 7-day-old and 2-to 5-month-old mice that were used for biochemical analysis were frozen in liquid nitrogen immediately after extraction. In some instances, mouse ventricular cardiomyocytes were isolated using a modified version of an isolation protocol described previously. 26
Cardiomyocyte Infection
Newborn (1-to 3-day-old, male and female) rat hearts were isolated, and neonatal rat cardiomyocytes were isolated and cultured, as we have described previously. 27 Neonatal rat cardiomyocytes were infected with green fluorescent protein-(GFP), ␥ 2 WT-, or ␥ 2 R302Qexpressing adenoviruses (AdGFP, Ad␥ 2 WT, or Ad␥ 2 R302Q, respectively) at a multiplicity of infection of 20. Forty-eight hours postinfection, cells were harvested as described. 28 
Cell Surface Area Measurements
The cardiomyocyte cell surface area measurements were obtained using ImagePro Plus software (MediaCybernetics, Bethesda, Md). [ 3 H]phenylalanine (1 Ci/mL) was added to isolated neonatal rat cardiomyocytes for 24 hours, and incorporation was determined, as described previously. 29
[ 3 H]Phenylalanine Incorporation
Measurement of Nuclear Factor of Activated T Cells Activity
To determine nuclear factor of activated T cells (NFAT) transcriptional activity, cardiomyocytes were cultured as described earlier and infected with adenoviruses harboring either the GFP (AdGFP) or the NFAT-Luc-Promoter (AdNFAT; Seven Hills Bioreagents) and assayed for luciferase activity as we have described previously. 30 Luciferase activity was standardized to protein content.
In Vitro AMPK Assay
AMPK activity was measured using the in vitro AMPK peptide substrate activity assay as described previously. 31 
Immunoblot Analysis
Boiled samples of heart or isolated cardiomyocytes homogenates were subjected to SDS-PAGE in gels containing 5% to 10% acrylamide and transferred to nitrocellulose and immunoblotted, as described previously. 32
Histology
One-micrometer sections of human heart endomyocardial biopsy samples fixed in 10% formalin were prepared and stained with hematoxylin-eosin stain, as described previously. 24 The left atrial appendage samples were collected as part of a post-transplant assessment for the PRKAG2 sample and as part of a clinical evaluation following a clinically indicated procedure for the "control" sample.
Glycogen Assay
Glycogen was extracted from frozen powdered mouse heart ventricular tissue or isolated cardiomyocytes, converted to glucose, and quantified using a range of glucose standards as described previously. 33 Glycogen was measured as micromole glucosyl units per gram wet weight of tissue or cells.
Measurement of Glycogen Synthase and Phosphorylase Activity
Activity was measured in cardiomyocyte homogenates essentially as described previously. 34, 35 
Measurement of Glycolytic Rates in Isolated Cardiomyocytes
Rates of glycolysis were measured using 5-[ 3 H] D-glucose as described by Folmes et al. 36 
Statistical Analysis
All data are presented as meanϮSEM. For comparison of 3 groups, ANOVA followed by the Bonferroni multiple comparisons test was used for the determination of statistical analysis. For comparison with AdGFP (set at an arbitrary value of 1), a 1-sample t test to a hypothetical mean was used. For comparison of 2 groups, a 2-tailed t test was used. A value of PϽ0.05 was considered significant.
Results
AMPK Activity and Subunit Expression
To confirm that hearts from TG␥ 2 R302Q mice demonstrated reduced AMPK activity as published previously, 24 whole heart homogenates were assayed for AMPK activity. Although hearts from both ␥ 2 wild-type overexpressing transgenic mice (TG␥ 2 WT) and ␥ 2 mutant overexpressing transgenic mice (TG␥ 2 R302Q) displayed decreases in AMPK activity compared with nontransgenic (NTG) hearts, AMPK activity in TG␥ 2 R302Q hearts was also significantly decreased compared with TG␥ 2 WT hearts ( Figure 1A ). Consistent with the reductions in total AMPK activity, ␣ 1 and ␣ 2 activities were both reduced to Ϸ50% of NTG levels in TG␥ 2 WT hearts, whereas the activities of both isoforms in TG␥ 2 R302Q hearts were decreased to Ϸ35% (data not shown). These data indicate that there are no specific effects of the mutation on either of the 2 catalytic isoforms of AMPK. In agreement with an overall decrease in AMPK activity, AMPK␣ phosphorylation at Thr172, a surrogate marker of the in vivo activation status of AMPK, was significantly reduced in hearts from TG␥ 2 R302Q mice compared with NTG and TG␥ 2 WT ( Figure 1B) . Interestingly, the ␥ 2 subunit was more highly expressed in the TG␥ 2 WT mouse hearts as compared with the TG␥ 2 R302Q mouse hearts, whereas ␥ 2 was not detected in NTG hearts at this exposure ( Figure 1C ). Although the expression of all other subunits was unchanged (data not shown), expression of ␤ 2 was also increased in both TG␥ 2 WT and TG␥ 2 R302Q mouse hearts as compared with NTG hearts ( Figure 1D) .
In contrast to the findings in hearts from transgenic mice, acute adenoviral-mediated expression of the ␥ 2 mutant (Ad␥ 2 R302Q) in isolated cardiomyocytes resulted in significantly higher AMPK activity ( Figure 1E) , with a trend to increase phosphorylation of the AMPK␣ subunit ( Figure 1F ) compared with control GFP-expressing cardiomyocytes (AdGFP). This increase in AMPK activity was also observed in hearts from 7-day-old TG␥ 2 R302Q mice ( Figure 1G ). Consistent with activation of AMPK, phosphorylation of acetyl CoA carboxylase, a downstream target of AMPK, was also significantly increased in ␥ 2 R302Q expressing cardiomyocytes compared with control (1.63Ϯ0.15-fold increase, PϽ0.05 versus control). Together, these data suggest that the reduction in AMPK activity observed in hearts from adult transgenic mice is likely a secondary effect rather than a direct result of the mutation per se. Interestingly, as observed in adult transgenic mice, the ␥ 2 WT subunit was present at higher levels than the ␥ 2 R302Q subunit in adenovirally transduced cardiomyocytes ( Figure 1H ), whereas expression of the ␤ 2 subunit was increased in both groups compared with GFP control ( Figure 1I ), suggesting that increased ␥ 2 levels may have a specific effect on ␤ 2 expression and/or stability.
The Development of Cardiac Hypertrophy
TG␥ 2 R302Q mice exhibited significant cardiac hypertrophy as indicated by the increase in heart weight (HW) ( Figure 2A ) compared with NTG and TG␥ 2 WT mice without a significant change in body weight (34.2Ϯ2.7 g, 27.6Ϯ1.0 g, 35.2Ϯ3.0 g for NTG, TG␥ 2 WT, and TG␥ 2 R302Q, respectively, PϭNS). Although many different myocardial cell types may contribute to increased HW/body weight, we show a direct increase in cardiomyocyte size in TG␥ 2 R302Q mice as compared with both NTG and TG␥ 2 WT controls ( Figure 2B ). Interestingly, TG␥ 2 WT mice also developed a significant increase in HW and an increase in cardiomyocyte cell surface area compared with NTG controls (Figure 2A and 2B, respectively), suggesting that expression of the nonmutated form of the ␥ 2 subunit also has a modest effect on cardiomyocyte growth. As we have previously shown that AMPK is a negative regulator of hypertrophy 29 and that inhibition of AMPK signaling may lead to a permissive environment for development of hypertrophy, 37 the inhibition of AMPK activity observed in both transgenic mouse models may contribute to the hypertrophic phenotype in these mice. However, phosphorylation of both Akt and p70S6K at their activating sites 38 was significantly decreased in the TG␥ 2 R302Q hypertrophic hearts compared with NTG hearts ( Figure 2C and 2D, respectively), suggesting that protein synthesis is not increased in adult TG␥ 2 WT or TG␥ 2 R302Q mouse hearts. In addition, acute expression of either the ␥ 2 WT or the ␥ 2 R302Q subunit in isolated cardiomyocytes did not result in increased cardiomyocyte size ( Figure 2E ), accelerated protein synthesis (basal or phenylephrine stimulated; Figure 2F ), or stimulation of prohypertrophic growth pathways ( Figure 2G ), suggesting that alterations in AMPK activity by these mutations do not promote cardiomyocyte cell growth by means of conventional mechanisms.
Glycogen Deposition
Humans with the ␥ 2 R302Q mutation develop PRKAG2 syndrome, a characteristic of which is excessive glycogen accumulation within the cardiomyocytes. Previous studies have shown that large vacuoles detected with hematoxylineosin staining of cardiomyocytes are representative of areas of glycogen deposition. 22 Consistent with this study and positive PAS staining in TG␥ 2 R302Q mouse hearts, 24 large vacuoles and distended cardiomyocytes, indicative of glycogen accumulation, were evident in the atria of a patient with the ␥ 2 R302Q mutation ( Figure 3A ) but were absent in the atria of a patient without this mutation ( Figure 3B ). In agreement with these data and previous results, 24 TG␥ 2 R302Q mouse hearts displayed a significant 37-fold increase in glycogen compared with NTG hearts ( Figure 3C ). In addition, TG␥ 2 WT hearts had a 10-fold increase in glycogen compared with NTG hearts but still had significantly lower glycogen levels than TG␥ 2 R302Q hearts ( Figure 3C ). In agreement with these findings, acute expression of either the ␥ 2 WT or the ␥ 2 R302Q Figure 1 . AMPK activity is differentially affected by acute and chronic expression of ␥ 2 R302Q. Whole heart homogenates (nϭ6, 7) from adult TG␥ 2 WT and TG␥ 2 R302Q mice display decreased AMPK activity (pmol/min/mg protein) compared with NTG mice (A) whereas AMPK activity is increased in cell lysates (nϭ4) from adenovirally transduced cardiomyocytes expressing ␥ 2 R302Q (Ad␥ 2 R302Q) (E) and in heart homogenates from 7-day-old TG␥ 2 R302Q mice (G). Phosphorylation of AMPK␣ (Thr172) is reduced in TG␥ 2 R302Q heart homogenates (B) and unchanged in cell lysates from cardiomyocytes expressing ␥ 2 R302Q (F), as measured by immunoblot analysis using antiphospho-AMPK␣ (Thr 172) and antitotal-AMPK␣ antibodies. Expression of ␥ 2 is increased in whole heart homogenates (C) and in cell lysates from cardiomyocytes expressing ␥ 2 WT (H), whereas ␤ 2 is increased in heart homogenates (D) and cell lysates from cardiomyocytes expressing either ␥ 2 R302Q or ␥ 2 WT (I), as measured using anti-AMPK␥ 2 , anti-AMPK␤ 2 , and antiactin antibodies. ***PϽ0.001 versus NTG or AdGFP; **PϽ0.01 versus NTG or AdGFP; ##PϽ0.01 versus TG␥ 2 WT or Ad␥ 2 WT; *PϽ0.05 versus NTG or AdGFP; and #PϽ0.05 versus TG␥ 2 WT or Ad␥ 2 WT. mutation in isolated cardiomyocytes also significantly increased glycogen content (70% and 270% versus control, respectively; Figure 3D ), suggesting that cellular alterations induced by the expression of either the WT or the mutant form of the ␥ 2 subunit can both promote glycogen accumulation.
Glycogen Turnover
To determine the mechanism by which glycogen accumulation occurs, we examined the enzymes involved in glycogen synthesis and degradation. In TG␥ 2 R302Q hearts, activity of glycogen synthase, the rate-limiting enzyme in glycogen synthesis, was significantly decreased compared with NTG Figure 2 . Cardiac hypertrophy is induced in transgenic mice with chronic expression of ␥ 2 WT and ␥ 2 R302Q but is absent in isolated cardiomyocytes acutely expressing ␥ 2 WT and ␥ 2 R302Q. HW (A) and ventricular myocyte cell surface area (99 to 125 cells/group isolated from 3 hearts in each group; B) were increased in adult TG␥ 2 WT and TG␥ 2 R302Q mice compared with NTG mice. Isolated neonatal rat cardiomyocytes transduced with adenoviruses expressing GFP, ␥ 2 WT, or ␥ 2 R302Q (AdGFP, Ad␥ 2 WT, or Ad␥ 2 R302Q, respectively) (238 to 255 cells/group; nϭ20) displayed no changes in cell surface area (E). Representative photographs of cardiomyocytes in each group are shown, where the white bar is 20 m (B and E-inset). Phosphorylation of Akt and p70S6K were decreased in whole heart homogenates from TG␥ 2 R302Q mice, as measured by antiphospho-Akt (Ser473), antiphospho-p70S6K (Thr389) and antiactin antibodies (C and D). Basal or phenylephrine-induced protein synthesis was not affected by increased ␥ 2 WT or ␥ 2 R302Q expression in neonatal rat cardiomyocytes, as measured by [ 3 H]Phenylalanine incorporation (F). Coinfection of neonatal rat cardiomyocytes with the NFAT-luciferase reporter gene (AdNFAT) and AdGFP, Ad␥ 2 WT, or Ad␥ 2 R302Q resulted in impaired NFAT transcriptional activity in cardiomyocytes expressing ␥ 2 WT or ␥ 2 R302Q (G). ***PϽ0.001 versus NTG or AdGFP; ###PϽ0.001 versus TG␥ 2 WT or Ad␥ 2 WT; **PϽ0.01 versus NTG or AdGFP; and *PϽ0.05 versus NTG.
Figure 3.
Glycogen levels are increased with acute and chronic expression of ␥ 2 WT and ␥ 2 R302Q. Hematoxylin-eosin staining of a human heart endomyocardial biopsy sample from a patient with the ␥ 2 R302Q mutation (A) shows evidence of glycogen accumulation (arrow points to a vacuolated myocyte indicative of glycogen deposition) compared with a control patient with no ␥ 2 R302Q mutation (B). Glycogen was measured from frozen powdered mouse heart ventricles from adult NTG, TG␥ 2 WT, and TG␥ 2 R302Q mice and from AdGFP, Ad␥ 2 WT, and Ad␥ 2 R302Q infected cardiomyocytes. Myocardial glycogen was increased in TG␥ 2 WT and TG␥ 2 R302Q hearts (mol glucosyl units/gram wet weight of tissue, nϭ3, 4) and in Ad␥ 2 WT and Ad␥ 2 R302Q infected cardiomyocytes (standardized to AdGFP, nϭ7,8) (C and D). ***PϽ0.001 versus NTG or AdGFP; **PϽ0.01 versus NTG or AdGFP; ##PϽ0.01 versus TG␥ 2 WT or Ad␥ 2 WT; *PϽ0.05 versus NTG or AdGFP; and #PϽ0.05 versus TG␥ 2 WT or Ad␥ 2 WT.
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The PRKAG2 R302Q Mutation and Myocardial Glycogen hearts ( Figure 4A ). Consistent with this, inhibitory phosphorylation of GS was significantly increased compared with both NTG and TG␥ 2 WT hearts ( Figure 4B and 4C) , and GS protein levels were significantly reduced compared with TG␥ 2 WT hearts ( Figure 4B and 4D ). This inhibition of GS is likely a compensatory mechanism resulting from the profound glycogen accumulation in these hearts. As observed with other parameters, GS activity and phosphorylation in TG␥ 2 WT hearts were intermediate between NTG and TG␥ 2 R302Q hearts ( Figure 4A and 4C, respectively). In addition to changes in GS activity and phosphorylation, glycogen phosphorylase (GP) activity was slightly but significantly reduced in TG␥ 2 R302Q hearts compared with NTG and TG␥ 2 WT hearts, indicating a potential impairment in glycogen mobilization ( Figure 4E ). Paradoxically, cardiomyocytes acutely expressing ␥ 2 R302Q exhibited no change in GS activity ( Figure 4F ) or phosphorylation ( Figure 4G and 4H); however, GS expression was significantly increased compared with controls ( Figure 4G and 4I ). In addition, GP activity was unchanged in cardiomyocytes expressing either ␥ 2 R302Q or ␥ 2 WT compared with control ( Figure 4J ). Although we do not provide evidence explaining why activities of GS and GP were unchanged in cardiomyocytes expressing either ␥ 2 R302Q or ␥ 2 WT, it is possible that the assay in cardiomyocytes is not sensitive enough to detect subtle changes in GS and GP activities that may be occurring in these cells.
Glucose Handling
Because the majority of glucose provided for glycogen synthesis comes from an increase in glucose uptake or a shunting of glucose away from glycolysis, we investigated glycolysis and glucose uptake in our models. Glycolytic metabolism of exogenous glucose was not altered in either the transgenic mice (G. Lopaschuk, personal communication) or in the isolated cardiomyocytes expressing the ␥ 2 R302Q mutation ( Figure 5A ). Given the increase in glycogen levels and unchanged rates of glycolysis in the cardiomyocytes expressing the ␥ 2 R302Q mutation, the calculated glucose uptake in cells expressing ␥ 2 R302Q was 1.76-fold higher than controls ( Figure 5B ). In addition, although activation of Akt was not changed (data not shown), phosphorylation of the Akt substrate of 160 kDa (AS160) was significantly increased in cardiomyocytes expressing ␥ 2 R302Q compared with control ( Figure 5C ). Interestingly, total protein levels of AS160 were also increased in cardiomyocytes expressing ␥ 2 R302Q compared with controls ( Figure 5D ). Although this increase in total protein levels of AS160 prevented a significant increase in the P-AS160/AS160 ratio (data not shown), the upregulation of both P-AS160 and total AS160 may be sufficient to promote glucose uptake especially since AS160 plays an important role in GLUT4 translocation to the membrane and increased glucose transport. 39 Despite this rationale, there did not seem to be an increase in GLUT4 in the plasma membrane in ␥ 2 R302Q-expressing cardiomyocytes as compared with controls (data not shown). In contrast to these findings in cardiomyocytes acutely expressing ␥ 2 R302Q, Akt phosphorylation was decreased ( Figure 2C ) and both P-AS160 and total AS160 expression were significantly reduced in the TG␥ 2 R302Q hearts compared with NTG hearts (Figure 5E and 5F, respectively), potentially as a chronic compensatory mechanism to prevent further glucose uptake and consequent glycogen accumulation.
Discussion
In this study, we focused on the acute effects of expression of both ␥ 2 WT and ␥ 2 R302Q in the control of AMPK phosphorylation and activity and compared these effects to the longterm, potentially compensatory effects of transgenic overexpression of these same proteins. In contrast to hearts from transgenic mice expressing the ␥ 2 N488I mutation, hearts from TG␥ 2 R302Q mice display reduced AMPK activity as compared with hearts from wild-type mice, which was attributed to decreases in both AMPK ␣ 1 and ␣ 2 subunit activity. However, consistent with our hypothesis that acute expression of the ␥ 2 mutant may have differential effects compared with chronic expression, acute expression of the ␥ 2 R302Q mutation in hearts from 7-day-old transgenic mice and in isolated cardiomyocytes resulted in a significant activation of AMPK. This initial increase in AMPK activity is consistent with that of mice with a ␥ 2 N488I mutation, where AMPK activity was increased in hearts from 7-day-old transgenic mice but not in hearts from older transgenic mice. 25 As our isolated cardiomyocyte data show that the ␥ 2 R302Q mutation is an activating mutation, the data obtained from the mouse models suggest that there is likely an inhibitory feedback mechanism that is responsible for decreased AMPK activity in the adult mouse heart expressing the ␥ 2 R302Q mutation. Although we do not provide evidence for this, we propose that the profound glycogen deposition in hearts from TG␥ 2 R302Q mice may be responsible for decreased myocardial AMPK activity in these mice as suggested previously. 25 Although the ␥ 2 R302Q mouse model used in this study differs from other mouse models expressing ␥ 2 mutations in terms of AMPK activity, 22 there are still consistencies between the models. For example, the TG␥ 2 R302Q mice also developed significant myocardial hypertrophy, which is in agreement with another transgenic mouse model expressing a mutated form of the ␥ 2 protein. 22 However, given that Figure 5 . Mechanisms involved in the regulation of glucose uptake and metabolism are differentially regulated by acute and chronic expression of ␥ 2 R302Q. Glycolysis was unchanged in isolated neonatal rat cardiomyocytes expressing GFP, ␥ 2 WT, or ␥ 2 R302Q (A). Glucose uptake (calculated based on numbers from glycolysis and glycogen) was increased in ␥ 2 R302Q-expressing cells (B). AS160 phosphorylation (C) and expression (D) were increased in cell lysates from ␥ 2 R302Q-expressing cardiomyocytes, as measured by antiphospho ser/thr Akt substrate, anti-AS160, and antiactin antibodies. AS160 phosphorylation (E) and expression (F) were decreased in TG␥ 2 R302Q heart homogenates, as measured by antiphospho ser/thr Akt substrate, anti-AS160, and antiactin antibodies. *PϽ0.05 versus NTG or AdGFP or ** PϽ0.01 versus NTG or AdGFP.
isolated cardiomyocytes acutely expressing the ␥ 2 R302Q mutation did not display evidence of growth, NFAT activation, or increased protein synthesis, our data suggest that the hypertrophy observed in the transgenic mice likely occurs by means of nonconventional mechanisms. In support of this, the phosphorylation status of Akt and p70S6K, which are normally increased in conventional hypertrophy, were reduced in the hearts of TG␥ 2 R302Q mice. However, consistent with glycogen accumulation inducing myocardial growth through nonconventional means, 17 hearts from TG␥ 2 R302Q mice displayed a significant 37-fold increase in glycogen compared with NTG hearts. Because humans possessing the ␥ 2 R302Q mutation also have profound glycogen accumulation, our study supports the notion that glycogen deposition and associated water accumulation may be the underlying cause of the cardiac hypertrophy also observed in a subgroup of this patient population. 15 An interesting finding in this study was that expression of the ␥ 2 WT protein also induced a cardiac phenotype in transgenic mice that was less severe than that observed in TG␥ 2 R302Q mice. Indeed, hearts from TG␥ 2 WT displayed a 50% reduction in AMPK activity, an 84% increase in HW, and a 10-fold increase in glycogen compared with NTG mice, indicating that a component of the cardiac phenotype observed in the TG␥ 2 R302Q mice may be related to simple overexpression of the ␥ 2 subunit. Although we cannot explain why expression of the ␥ 2 WT subunit results in similar, albeit less marked changes compared with expression of the ␥ 2 R302Q mutant, the intermediate phenotype may be because of the much higher expression level of the ␥ 2 subunit in TG␥ 2 WT hearts. While it would be reasonable to assume that the elevated level of ␥ 2 WT protein in the mouse heart is due to variations in genomic incorporation of the ␥ 2 WT transgene compared with ␥ 2 R302Q, this is likely not the case given that the same expression profile is observed with epichromosomal expression of the ␥ 2 subunits using adenoviral delivery. Although these data suggest that the stability of the ␥ 2 protein may be influenced by the R302Q mutation, we still cannot explain how expression of the ␥ 2 WT protein also produces profound glycogen deposition. However, while the expression levels of the majority of the other subunits of AMPK were unaltered, protein expression of the AMPK␤ 2 subunit was also significantly increased in hearts and in cardiomyocytes expressing either the WT or the R302Q mutant forms of ␥ 2 . As previous work using AMPK ␣ 2 Ϫ/Ϫ mice demonstrate a correlation between ␤ 2 expression (which possesses a glycogen binding domain) and glycogen levels, 40 increased expression of the ␤ 2 subunit in this study may contribute to the glycogen accumulation in hearts and in isolated cardiomyocytes.
To better characterize the mechanisms involved in glycogen accumulation in isolated cardiomyocytes and transgenic mice expressing ␥ 2 WT and the ␥ 2 R302Q mutation, we first examined the glycogen synthesis pathway. Although GS protein levels were increased in isolated cardiomyocytes acutely expressing ␥ 2 R302Q, GS protein content and activity were significantly reduced in TG␥ 2 R302Q hearts, likely in response to massive glycogen accumulation. Surprisingly, despite the 10-fold increase in glycogen content, GS expres-sion and activity were not reduced in TG␥ 2 WT hearts. In fact, GS protein content was significantly increased compared with NTG, suggesting that a Ͼ10-fold increase in glycogen is required before any compensatory mechanisms are initiated. As the glucose necessary for glycogen synthesis must come from either increased glucose uptake or decreased glycolysis, we also measured these parameters in isolated cardiomyocytes. The rates of glycolytic metabolism of exogenous glucose were not reduced in isolated cardiomyocytes acutely expressing the ␥ 2 R302Q mutation. Interestingly, cardiomyocytes expressing the ␥ 2 R302Q mutation also do not have increased GLUT4 protein in the plasma membrane nor were we were able to detect increased glucose uptake compared with controls. Although we cannot explain this lack of effect, it may be because of the sensitivity of the glucose uptake method used in this study. Indeed, both calculated glucose uptake as well as expression and phosphorylation of AS160, an enzyme involved in GLUT4 translocation to the plasma membrane, 39 are increased in isolated cardiomyocytes acutely expressing ␥ 2 R302Q compared with control, suggesting that glucose uptake is likely elevated in these cells. As a result, we propose that acute expression of the ␥ 2 R302Q mutation results in an activation of the AMPK holoenzyme and an upregulation of both AS160 phosphorylation/expression and GS expression, resulting in increased glucose uptake and glycogen synthesis. Conversely, long-term expression of this mutation in transgenic mice results in an inactivation of AMPK, a downregulation of Akt phosphorylation, decreased AS160 phosphorylation/expression, and an inhibition of GS, potentially as a compensatory mechanism to prevent further deleterious accumulation of glycogen. Whether the observed effects are a result of activation and/or inhibition of various transcription factors is currently being investigated.
Finally, as our data have shown that AMPK activity is increased to a similar extent in isolated cardiomyocytes expressing either the ␥ 2 R302Q mutation or the ␥ 2 WT while glycogen content is significantly higher in ␥ 2 R302Qexpressing cells, it is tempting to speculate that glycogen levels and not alterations in AMPK activity per se may be responsible for the Wolff-Parkinson-White phenotype. In fact, although the TG␥ 2 WT mice do display a less marked phenotype, this study highlights that inhibition of AMPK activity, a 10-fold increase in glycogen, and modest hypertrophic growth are not sufficient for the development of preexcitation. What seems to be a necessary component of Wolff-Parkinson-White in the ␥ 2 mutation models is profound glycogen accumulation, independent of AMPK activity, as originally hypothesized. 41 Indeed, despite variable effects of the 3 different mutations (ie, ␥ 2 R302Q, ␥ 2 N488I, and ␥ 2 R531G) on AMPK activity during different stages of life, what is consistent in all mouse models is the extreme glycogen deposition observed in the cardiomyocyte. 17, 23 Taken together, these data suggest that excessive glycogen accumulation is the major contributor to the cause of Wolff-Parkinson-White syndrome as opposed to AMPK activity per se. In addition, the phenotype observed in the TG␥ 2 WT mice highlights the confounding factors associated with the existing transgenic mice expressing cardiomyocyte-restricted AMPK␥ 2 mutations. As such, it is becoming increasingly evident that a knock-in mouse is the ideal and necessary model to use to study the cardiac effects of these mutations.
In conclusion, our results serve to highlight the complexity of AMPK signaling in the development of glycogen storage cardiomyopathy and help to resolve the controversy surrounding the ␥ 2 R302Q mutation with respect to the effect that it has on AMPK activity. 24 As such, these findings offer valuable insights into the early and late signaling mechanisms that underlie the excessive glycogen deposition associated with PRKAG2 cardiomyopathy. These findings are particularly relevant given the recent advancements made in the identification of AMPK activators, 11 and the potential cardiac side effects that may be associated with these agents.
